No case-study findings are currently published.
Cohort size, collection start date, observation windows, analysis plans, and results have not been established for public reporting on this website. Any future report will identify what is known, what is unknown, and which values are estimates.
How Halflife Labs collects and aggregates protocol outcome data.
All data is collected from Halflife app users who explicitly opt in to contribute anonymised protocol data to research. Opt-in is disabled by default and can be revoked at any time.
Data is aggregated at the cohort level. Each case study defines a cohort by compound combination, dosing range, and minimum observation window. Individual records are never published or shared.
All studies are observational, non-interventional, and retrospective. Halflife does not assign protocols, control dosing, or influence user behavior. Outcome metrics are derived from self-reported injection logs and weight entries.
Access aggregated protocol data for research, integration, or licensing.
No protocol-outcome dataset is currently documented as available. Future access terms, if any, are unknown until confirmed in writing.
Anonymised dataset access and IRB partnership framework for publishable studies on GLP-1 and peptide protocol outcomes.
API-first protocol tracking and adherence monitoring integration for patient portals.
Longitudinal real-world evidence datasets for pharmaceutical companies and market research firms.